A pilot study to assess the efficacy and safety of dasatinib after allogeneic stem cell transplantation in patients with de novo Philadelphia positive (bcr-abl+) acute lymphoblastic leukemia

ISRCTN ISRCTN44728648
DOI https://doi.org/10.1186/ISRCTN44728648
Secondary identifying numbers DASA-TRAS
Submission date
25/10/2010
Registration date
04/11/2010
Last edited
04/11/2010
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Guillermo Sanz
Scientific

Hospital la Fe
Avda. Campanar, 21.
Valencia
46009
Spain

Study information

Study designMulticentre pilot single arm open label Phase II study
Primary study designInterventional
Secondary study designNon randomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use contact details below to request a patient information sheet
Scientific titleMulticenter, non-randomised Phase II pilot study to assess the efficacy and safety of dasatinib after allogeneic stem cell transplantation in patients with de novo Philadelphia positive (bcr-abl +) acute lymphoblastic leukemia
Study acronymDASA-TRAS
Study objectivesTreatment with dasatinib 100 mg daily (QD) is safe and efficacious when given to patients with Philadelphia chromosome positive (Ph+) Acute Lymphoblastic Leukaemia (ALL) in the post Stem Cell Transplantation (SCT) setting
Ethics approval(s)The local ethics committee (Comité Ético Investigación Clínica [CEIC], Hospital La Fe) approved on the 19th of December 2009
Health condition(s) or problem(s) studiedAcute lymphoblastic leukaemia (ALL); Philadelphia chromosome positive (Ph+/BCR-ABL+)
InterventionTreatment with 100 mg QD of dasatinib (Sprycel) administered orally as continuous daily dosing (CDD)
Intervention typeOther
Primary outcome measureDisease Free Survival (DFS) at 2 years
Secondary outcome measures1. Duration of hematologic, cytogenetic and molecular remission
2. Relapse rate at 2 years
3. Survival at 2 years
4. Overall DFS
5. Overall Survival (OS)
Overall study start date08/04/2010
Completion date08/04/2014

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants30 Patients
Key inclusion criteria1. Adult patients ≥ 18 years
2. Diagnostic confirmation of de novo Ph+ (BCL-ABL translocation) ALL
3. Patients in first/second complete remission (CR) (assessed by cytology, karyotyping, fluorescent in-situ hybridisation [FISH] and BCR/ABL reverse transcriptase- polymerase chain reaction [RT-PCR]) at transplantation
4. Patients with sustained hematologic and cytogenetic CR at the time of study entry
5. Any modality of allogeneic SCT
6. Patients are in day +180 (± 2 weeks) after allogeneic SCT with stable graft (patients may sign inform consent from day +166 on, but will not start study treatment until they have reached day +180 and not later than day + 194)
7. Ability to understand and voluntarily sign the informed consent form
8. Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy and have a negative pregnancy test, a maximum of 48 hours prior to study drug start
Key exclusion criteria1. Patients with Eastern Cooperative Oncology Group (ECOG) 3-4 at study entry
2. Any of the following laboratory abnormalities:
2.1. Absolute neutrophil count < 1.5 x 109/l or platelets < 75 x 109/l
2.2. Serum creatinine > 2.0 mg/dl (177 mmol/l)
2.3. Serum glutamic oxalacetic transaminase (SGOT) or serum glutamate piruvate transaminase (SGPT) > 5,0 x upper limit of normal (ULN)
2.4. Total bilirrubin > 3 mg/dl
3. Known HIV infection or any other uncontrolled infection at study entry
4. Known pleural effusion of any grade at study entry
5. Morphologic or cytogenetic or molecular relapse at study entry
6. Evidence of digestive dysfunction that could prevent administration of study therapy
7. Prior therapy with dasatinib
8. Other concurrent malignancy at study entry
9. Uncontrolled or significant cardiovascular disease, including myocardial infarction within 6 months, uncontrolled angina within 3 months, prolonged QT interval, congestive heart failure within 3 months and clinically significant ventricular arrhythmias
10. Any psychiatric condition that could prevent patient from signing the informed consent or could put the patient at an unacceptable risk in case of participating in the trial
11. Subjects enrolled in another clinical trial at study entry. If patients have received other investigational agent, a minimum of 30 days wash-out period must have elapsed.
Date of first enrolment08/04/2010
Date of final enrolment08/04/2014

Locations

Countries of recruitment

  • Spain

Study participating centre

Hospital la Fe
Valencia
46009
Spain

Sponsor information

Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH) (Spain)
Research organisation

C/ Fortuna, nº 51, local 5
Madrid
28010
Spain

ROR logo "ROR" https://ror.org/015xc6321

Funders

Funder type

Research organisation

Spanish Group of Hematopoietic Transplantation and Cell Therapy (Grupo Español de Transplantes Hematopoyéticos y Terapia celular [GETH]) (Spain)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan